Hepatitis Forums

Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on October 16, 2019, 10:38:18 am

Title: Baraclude and Viread as Treatment for Hepatitis B Yield Comparable Prognoses
Post by: Hep Editors on October 16, 2019, 10:38:18 am
Whether hepatitis B virus (HBV) is treated with Baraclude (entecavir) or Viread (tenofovir disoproxil fumarate), there is no difference in prognosis when it comes to rates of hepatocellular carcinoma (HCC, the most common form of liver cancer) or the composite outcome of liver transplant or death. So found a recent study by a team of South Korean researchers.

Publishing their findings in the Journal of Hepatology, a research team led by Beom Kyung Kim, MD, of the department of internal medicine at Yonsei University College of Medicine in Seoul, and Yeon Seok Seo, MD, of the department of internal medicine at Korea University College of Medicine, also in Seoul, enrolled in their study 2,897 people with HBV who were first-timers to treatment and who were started on either Baraclude or Viread between 2012 and 2014.

For more...
https://www.hepmag.com/article/baraclude-viread-treatment-hepatitis-b-yield-comparable-prognoses